Reinventing the vaccine clinical trial under modern scientific pressures
Dr David McIntosh, Global Scientific Affairs Senior Expert, Novartis Vaccines & Diagnostics joined us at the World Vaccine Congress in Washington 2012 to give his view on the changing nature of vaccine trials in light of modern scientific pressures.
The themes covered included:
- New vaccines and their implications for clinical trials
- Increased costs, globalisation, outsourcing, regulatory harmonisation, the rise of electronic data capture, clinical trial transparency and patient centricity
- Harnessing new communication to increase efficiency an and speed of trials
- What does the future hold for the current vaccine clinical trial model, and what solutions can be presented to ensure a successful â€˜reinvention'?
- Reverse vaccinology is a new technique for identifying targets
- Meningococcal serogroup B vaccine promises to be the first vaccine invented in this way
- Conjugate vaccines
- Herd protection is an important added benefit Healthcare associated infections
- Staphylococcus aureus: considerable antigenic diversity and problem of MRSA
- Maternal immunisation
- Group B streptococcus (GBS) vaccine – new frontier